MARKET

BIOC

BIOC

Biocept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2670
-0.0079
-2.87%
Closed 19:54 04/02 EDT
OPEN
0.2920
PREV CLOSE
0.2749
HIGH
0.2920
LOW
0.2650
VOLUME
6.02M
TURNOVER
--
52 WEEK HIGH
2.110
52 WEEK LOW
0.2112
MARKET CAP
29.02M
P/E (TTM)
-0.1001
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BIOC stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.

EPS

BIOC News

More
  • Australia Patent Issued for Primer-Switch Mutation Detection and Amplification Platform
  • PR Newswire · 22h ago
  • For Penny Investors, Biocept Stock Makes a Good Speculative Play
  • SmarterAnalyst · 1d ago
  • US$1.00: That's What Analysts Think Biocept, Inc. (NASDAQ:BIOC) Is Worth After Its Latest Results
  • Simply Wall St. · 5d ago
  • Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician Association
  • PR Newswire · 03/26 13:05

Industry

Medical Equipment, Supplies & Distribution
+2.77%
Healthcare Equipment & Supplies
+3.32%

Hot Stocks

Symbol
Price
%Change

About BIOC

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
More

Webull offers kinds of Biocept Inc stock information, including NASDAQ:BIOC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOC stock news, and many more online research tools to help you make informed decisions.